IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaji, Y.
Right arrow Articles by Amano, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaji, Y.
Right arrow Articles by Amano, S.
(Investigative Ophthalmology and Visual Science. 2000;41:362-368.)
© 2000 by The Association for Research in Vision and Ophthalmology, Inc.

Advanced Glycation End Products in Diabetic Corneas

Yuichi Kaji1, Tomohiko Usui1, Tetsuro Oshika1, Masao Matsubara1, Hidetoshi Yamashita1, Makoto Araie1, Toshinori Murata2, Tatsuro Ishibashi2, Ryoji Nagai3, Seikoh Horiuchi3 and Shiro Amano1

1 From the Department of Ophthalmology, University of Tokyo School of Medicine, Japan; the 2 Department of Ophthalmology, University of Kyushu School of Medicine, Fukuoka, Japan; and the 3 Department of Biochemistry, University of Kumamoto School of Medicine, Japan.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
PURPOSE. Corneal complications are often associated with diabetes mellitus and can be vision threatening. Corneas in diabetic patients are exposed to increased glucose concentration despite cornea’s avascular property, and this condition may contribute to the accumulation of advanced glycation end products (AGEs). The focus of this study was to examine the role of AGEs in the pathogenesis of diabetic keratopathy.

METHODS. An anti-AGE monoclonal antibody (6D12), which recognizes a N{epsilon}-carboxymethyl lysine (CML)–protein adduct as an epitope, was prepared. Immunohistochemical localization of CML was examined in human age-matched diabetic and nondiabetic corneas (8 of each). In vitro, type I collagen–, type IV collagen–, or laminin-coated 96-well plates were glycated by glucose-6-phosphate. In some experiments, aminoguanidine was present in the incubation mixture. The amounts of CML-protein adducts in the extracellular matrix (ECM) were determined by enzyme-linked immunosorbent assay using 6D12. SV40–immortalized human corneal epithelial cells were seeded onto modified or unmodified ECM in 96-well plates and allowed to attach for 3 hours. Attached cells were fixed, and the areas of attached cells in each condition were measured. Attached cells without fixation were removed, and cell number was counted.

RESULTS. In all of the 8 diabetic corneas, CML immunoreactivity was observed in the epithelial basement membrane, whereas CML immunoreactivity was not found in the corresponding area in 7 of 8 nondiabetic corneas. In vitro, nonenzymatic glycation of laminin on the culture dish attenuated adhesion and spreading of corneal epithelial cells. The presence of aminoguanidine in the incubation mixture during glycation inhibited CML formation and promoted the adhesion and spreading of corneal epithelial cells in a dose-dependent manner.

CONCLUSIONS. The accumulation of AGEs on the basement membrane, particularly on laminin, may play a causative role in the corneal epithelial disorders of diabetic patients.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Corneal abnormalities in patients with diabetes mellitus have been demonstrated and have been termed "diabetic keratopathy."1 Histologically, thickening of the corneal epithelial basement membrane2 3 4 and morphologic changes of the corneal epithelium and endothelium5 6 7 have been reported. Clinically, the damage to the corneal epithelium during vitreous surgery and retinal photocoagulation sometimes induces vision-threatening corneal complications such as persistent epithelial defect, recurrent erosion, and stromal edema in diabetic patients.8 9 10 11 Some reports have remarked that the activation of sorbitol pathway might be involved in the pathogenesis of diabetic keratopathy.12 13 However, the pathogenic mechanisms underlying those abnormalities are still unclear.

The accumulation of advanced glycation end products (AGEs) has been suggested as a pathogenic mechanism underlying diabetic complications such as nephropathy,14 retinopathy,15 and cataract.16 17 Chronic hyperglycemia leads, through early-stage products of nonenzymatic glycation such as Schiff bases and Amadori products, to the formation of AGEs on proteins. Among several structures reported so far, N{epsilon}-(carboxymethyl) lysine (CML) has been identified as a dominant AGE antigen in tissue proteins.18 19

Previous reports10 20 indicated that corneas in diabetic patients are exposed to increased glucose concentration despite the cornea’s avascular property. This condition may contribute to the accumulation of AGEs in diabetic corneas. However, the existence and the distribution of AGEs in diabetic corneas have not been examined. We prepared an anti-AGE monoclonal antibody and examined the role of AGEs in the pathogenesis of diabetic keratopathy.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Human Corneal Specimens
Sixteen human corneas were obtained from 16 autopsy cases within 6 hours postmortem. We examined 8 corneas from 8 patients with the history of diabetes mellitus (6 men and 2 women) and 8 corneas from 8 persons without the history of diabetes mellitus (5 men and 3 women). The mean ages of the diabetic and nondiabetic subjects were 69.9 ± 6.79 (mean ± SD; range, 58–80) and 64.1 ± 10.1 (range, 45–78) years, respectively. The averages of age in the two groups were not significantly different (Mann–Whitney U test, P = 0.21). The type of diabetes mellitus was non-insulin dependent in 7 patients and unknown in one patient. The average duration of diabetic history in 5 patients was 11.2 ± 3.6 years (range, 6–16). The duration of diabetic history was unknown in the remaining 3 patients. The diabetic retinopathy was present in 4 diabetic patients, and the presence or absence of diabetic retinopathy was unknown in the other 4 diabetic patients.

Antibody
An anti-AGE monoclonal antibody (6D12) was prepared as previously described.21 Briefly, mice were immunized with AGE-modified albumin, and the splenic lymphocytes from the immunized mouse were fused to myeloma cells. Culture supernatant of hybrid cells was screened by its reactivity to AGEs. The selected cell lines were injected into Balb/c mice for production of ascites. The antibody was purified by protein G–Sepharose DEAE–cellulose chromatography. Our recent study revealed that this antibody recognizes a CML-protein adduct as an epitope.19

Immunohistochemical Localization of CML
Formalin-fixed and paraffin-embedded corneas were cut into 3-µm-thick sections, deparaffinized by xylene, and dehydrated by graded ethanol. The sections were treated with 3% hydrogen peroxide in phosphate-buffered saline (PBS) for 15 minutes and then rinsed in PBS. To increase the immunoreactivity of AGEs, the sections were placed in 500 ml of 0.01 M of citric acid–buffered solution (pH 7.0) and applied to microwave (500 W) for 5 minutes.22 23 After thorough washing, the sections were incubated with the normal rabbit serum for 20 minutes at room temperature to avoid nonspecific binding of the antibodies. The sections were then incubated overnight at 4°C with 3 µg/ml of the anti-AGE monoclonal antibody (6D12) in PBS containing 1% of bovine serum albumin. Immunoreactivity was detected by the streptavidin–biotin–peroxidase method using a Histofine SAB-PO (M) kit (Nichirei, Tokyo, Japan) according to the manufacturer’s protocol. The final reaction product was visualized with 3,3'-diaminobenzidine tetrahydrochloride (DAB). We repeated the experiments three times.

Corneal Epithelial Cell Line and Culture Condition
We used immortalized human corneal epithelial cells with a recombinant SV40-adenovirus vector.24 This cell line exhibits a cobblestone–like appearance similar to that of basal cells of normal corneal epithelium in culture, and can differentiate in a multilayered fashion when grown at air-liquid interface on collagen gel. They were grown in supplemented hormone epithelial medium as previously described.24 The culture was maintained in a humidified atmosphere (95% air and 5% CO2) at 37°C.

In Vitro Glycation of Extracellular Matrix Components
Type I collagen–, type IV collagen–, or laminin-coated 96-well plates were purchased (Falcon, Oxnard, CA). According to the manufacturer’s information, the laminin was produced by mouse Engelbreth–Holm–Swarm tumor and mainly had laminin-1. To glycate extracellular matrix (ECM) components of cultured dishes, 200 µl of 50 mM glucose-6-phosphate (G-6-P; Wako, Osaka, Japan) in 0.2 M NaHPO4–buffered solution (pH 7.8) was added in each well under sterile conditions, and dishes were maintained at 37°C for 3 weeks. In some experiments, aminoguanidine (2–20 mM) was present in the incubation mixture. The control wells were incubated without G-6-P.

Measurement of CML Contents in ECM Components
The amounts of CML-protein adducts in ECM were determined by enzyme-linked immunosorbent assay (ELISA) using 6D12. The glycated and nonglycated wells were washed 3 times with PBS and blocked with 0.5% of gelatin hydrolysate (Sigma, St. Louis, MO) in 0.05 M carbonate–buffered solution (pH 9.6) for 1 hour. The wells were washed 3 times with washing buffer containing 0.05% of Tween-20 in PBS and were incubated for 1 hour with 100 µl/well of 0.1 mg/ml of the anti-AGE antibody (6D12) in dilution buffer containing 0.3% bovine serum albumin (Sigma) in washing buffer. The wells were then washed with washing buffer 3 times and incubated for 1 hour with 100 µl/well of horseradish peroxidase–conjugated anti-mouse IgG diluted 1:10,000. After a thorough washing, the wells were developed with 200 µl/well of substrate solution containing 0.55 mg/ml of ortho-phenylenediamine and 0.002% of hydrogen peroxide in 50 mM of citric acid–buffered solution (pH 5.0). The reaction was stopped by 50 µl/well of 1 M H2SO4, and the absorbance at 490 nm was measured using DigiScan Reader (ASYS Hitech GmbH, Eugendorf, Austria). The experiments were repeated 8 times.

Cell Spreading and Adhesion on ECM Components
Human corneal epithelial cells were seeded at 10,000 cells/0.25 ml onto modified or unmodified ECM in 96-well plates and allowed to attach for 3 hours. The cultured media and unattached cells were aspirated, and the wells were gently washed with PBS. Attached cells were fixed and stained with Diff-Quick staining set (International Reagents, Kobe, Japan), and random pictures of attached cells were taken under light microscope (Nikon, Tokyo, Japan) at the magnification of 200. By analyzing the pictures using NIH image, the areas of 50 attached cells in each condition were measured. Attached cells without fixation were removed by exposing each well to 0.25 ml of trypsin–EDTA (GIBCO, Grand Island, NY) for 20 minutes. Isoton solution (American Scientific Products, McGraw, IL) was added to the cell suspension to a final volume of 10 ml, and cell number was counted with a Coulter counter (type Z1). The experiments were repeated 8 times.

Statistical Analysis
The effect of glycation and aminoguanidine was analyzed by ANOVA. Additionally, the Scheffé multiple comparison test was used to compare the differences between all possible pairs of means within each experiment.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Immunohistochemical Localization of CML in Human Corneas
In all the examined diabetic corneas, CML immunoreactivity was observed at the site of the epithelial basement membrane (Figs. 1A 1B 1C) , whereas CML immunoreactivity was not found in the corresponding area in 7 of 8 nondiabetic corneas (Fig. 1D) . In one nondiabetic cornea obtained from 72-year-old man, CMLc immunoreactivity was observed at the site of epithelial basement membrane (Fig. 1E) . CML was detected in the endothelial cells of all the examined corneas from both diabetes (Fig. 1F) and nondiabetes (Fig. 1G) . Descemet’s membrane did not show CML immunoreactivity in the examined corneas from diabetes (Fig. 1F) or nondiabetes (Fig. 1G) .




View larger version (265K):
[in this window]
[in a new window]
  		Figure 1. Immunohistochemical localization of CML in diabetic (A, B, C, F) and nondiabetic (D, E, G) corneas. In all of the 8 diabetic human corneas, CML immunoreactivity was observed in the epithelial basement membrane area (arrowheads in A, B, C), whereas CML immunoreactivity was not found in the corresponding area in 7 of the 8 nondiabetic corneas (D). In one nondiabetic cornea obtained from a 72-year-old man, CML immunoreactivity was observed at the site of epithelial basement membrane (arrowheads in E). CML was detected in the endothelial cells of all the examined corneas from both diabetes (F) and nondiabetes (G). Descemet’s membrane did not show CML immunoreactivity in the examined corneas from diabetes (F) or nondiabetes (G). Magnification, x200.

 
Glycation of ECM
In the culture dishes without ECM, incubation with G-6-P induced little CML. In addition, incubation without G-6-P formed little CML in ECM. After incubation with G-6-P, CML was detected in the culture dishes with type I collagen, type IV collagen, and laminin. The presence of aminoguanidine in the incubation mixture during glycation dose-dependently inhibited CML formation with G-6-P (Fig. 2) .



View larger version (17K):
[in this window]
[in a new window]
  		Figure 2. Effects of incubation with G-6-P and aminoguanidine (AG) on glycation of ECM components. Incubation with G-6-P for 3 weeks induced glycation of type I collagen, type IV collagen, and laminin. Aminoguanidine dose-dependently inhibited the glycation of each ECM component. *P < 0.0001.

 
Effect of ECM Glycation on Attachment of Corneal Epithelial Cells
The numbers of attached corneal epithelial cells on glycated type I and type IV collagens did not significantly differ from those of attached cells on non-glycated type I and type IV collagens, respectively (Fig. 3) . In contrast, glycation of laminin significantly diminished the number of attached corneal epithelial cells. The presence of aminoguanidine in the incubation mixture during glycation dose-dependently increased the number of adherent cells on glycated laminin.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 3. Numbers of adherent corneal epithelial cells on glycated or nonglycated ECM components. Human corneal epithelial cells were seeded onto glycated or nonglycated ECM in 96-well plates and allowed to attach for 3 hours. Attached cells were removed, and cell number was counted. The numbers of attached corneal epithelial cells on glycated type I and type IV collagens did not significantly differ from those of attached cells on nonglycated type I and type IV collagens, respectively. In contrast, glycation of laminin significantly diminished the number of attached corneal epithelial cells. The presence of aminoguanidine (AG) during glycation dose-dependently increased the number of adherent cells on glycated laminin.

 
Effect of ECM Glycation on Spreading of Corneal Epithelial Cells
Glycation of type I and type IV collagens had no significant effect on the surface area of adherent cells (Fig. 4A ). The presence of aminoguanidine in the incubation mixture had no effect on the cell area. In contrast, glycation of laminin attenuated the spreading of cells. Most cells on glycated laminin were spherical (Fig. 4B) , whereas most cells on nonglycated laminin were elongated (Fig. 4C) . The surface area of adherent cells on glycated laminin was significantly smaller than that of cells on nonglycated laminin (Fig. 4A) . The presence of aminoguanidine in the incubation mixture during glycation dose-dependently increased the surface area of adherent cells on glycated laminin (Fig. 4A) .



View larger version (71K):
[in this window]
[in a new window]
  		Figure 4. Effect of ECM glycation on spreading of corneal epithelial cells. Human corneal epithelial cells were seeded onto glycated or nonglycated ECM in 96-well plates and allowed to attach for 3 hours. Attached cells were fixed, and the areas of 50 attached cells in each were measured. (A) Glycation of type I and type IV collagens had no significant effect on the surface area of adherent cells. The presence of aminoguanidine (AG) in the incubation mixture during glycation of type I and type IV collagens had no effect on the cell area. In contrast, glycation of laminin attenuated the spreading of cells. The surface area of adherent cells on glycated laminin was significantly smaller than that of cells on nonglycated laminin. The presence of aminoguanidine during glycation dose-dependently increased the surface area of adherent cells on glycated laminin. *P < 0.0001 (B and C) Most cells on glycated laminin were spherical (B), whereas most cells on nonglycated laminin were elongated (C). Magnification, x100.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Using the anti-AGE antibody (6D12), we previously found a positive correlation between AGE-immunoreactivity and aging in some tissues.17 25 To exclude the aging factor as much as possible and evaluate the effect of diabetic condition on CML accumulation in the cornea, we prepared age-matched diabetic and nondiabetic corneas. In all the examined diabetic corneas, CML immunoreactivity was observed in the epithelial basement membrane area, whereas CML immunoreactivity was not found in the corresponding area in most of the nondiabetic corneas. Considering the previous studies reporting that AGEs accumulate with increasing age in other tissues, it is somewhat puzzling that CML immunoreactivity was absent in most of the nondiabetic elderly subjects and that it was present in only one nondiabetic cornea from a subject (72-year-old) who was not the oldest among the nondiabetic group. One possibility for these points is that, in most of the nondiabetic corneas, the glucose concentration may not reach the level high enough for AGEs to be formed because of the cornea’s avascular property. Another possibility is that immunohistochemistry, being a qualitative method, might not be able to detect the amount of AGEs in a linear fashion. More quantitative methods such as high-performance liquid chromatography and ELISA could detect the amount of AGEs accumulated in the corneas of nondiabetic elderly subjects in a linear fashion.

Considering that laminin is a major component in the human corneal basement membrane26 27 28 and that the turnover rate of laminin is as slow as that of other components,29 30 it is likely that laminin in the basement membrane of diabetic cornea contains CML.

The mechanisms by which increased glucose concentration results in altered cell behavior might be multiple. We have examined the effects of one of these mechanisms, glycation of the matrix and its influence on the cell behavior. The presence of aminoguanidine during glycation inhibited the formation of CML on the matrix and regained adhesion and spreading of corneal epithelial cells on the matrix in a dose-dependent manner. These results indicate that glycation of the matrix plays a certain role in altered cell behavior induced by increased glucose concentration.

The results of the current in vitro and in vivo studies raise the following presumption: nonenzymatic glycation of ECM (particularly laminin) in the corneal epithelial basement membrane decreases adhesion and spreading of the corneal epithelial cells, leading to corneal epithelial disorders in diabetic patients. This presumption is compatible with the clinical observation that in corneal epithelial defects of diabetic patients, corneal epithelial cells proliferate onto the underlying stroma but often easily detach from the stroma.31 32 Previous studies have shown that nonenzymatic glycation of ECM weakens adhesion and spreading of mesangial cells, glomerular epithelial cells, and vascular endothelial cells and that it probably causes chronic diabetic complications such as nephropathy and atherosclerosis.33 34 35 36 Our results support the hypothesis that AGEs may be responsible for diabetic corneal epitheliopathy. However, we have not shown that the specific inhibition of AGEs’ formation normalizes corneal epithelial behavior in diabetic corneas. Additional experiments are needed to prove that AGEs are responsible for diabetic corneal epitheliopathy.

A recent study reported that the immunoreactivity for entactin/nidogen and for chains of laminin-1 and laminin-10 was very weak or absent in the corneal epithelial basement membrane of diabetics with diabetic retinopathy, whereas corneas from nondiabetic individuals or diabetics without diabetic retinopathy showed such alterations much less frequently.37 As they stated in their report, their results suggest that, as retinal diabetic disease worsens, concomitant alterations of the corneal epithelial basement membrane occur in parallel. They suggested that these alterations might be due to the action of growth factors or proteinases abnormally expressed in the eyes with diabetic retinopathy. In addition to those mechanisms, it is possible that advanced accumulation of AGEs concomitant with a long history of diabetes mellitus altered the immunoreactivity of the ECM components in the corneal epithelial basement membrane. This hypothesis should be confirmed in the future study using a greater number of corneas from diabetes, with or without diabetic retinopathy, and nondiabetes.

CML immunoreactivity was not observed in the Descemet’s membrane of diabetic or nondiabetic corneas, which is the basement membrane of the corneal endothelial cells. This result is somewhat puzzling because Descemet’s membrane should be exposed to a higher concentration of glucose than the epithelial basement membrane (being closer to the aqueous humor, which is the source of most of the corneal glucose). Why did Descemet’s membrane contain no CML immunoreactivity? One possibility is that high concentrations of oxygen may accelerate the formation of CML in the epithelial basement membrane. Considerable evidence shows that oxidative mechanism is involved in the process of AGEs’ formation.38 39 40 Because oxygen in the cornea is supplied primarily by diffusion from the tear fluid, the epithelial basement membrane should be exposed to a higher concentration of oxygen than Descemet’s membrane. Further experiments are necessary to determine the actual mechanisms of the discrepancy of CML immunoreactivity between epithelial basement membrane and Descemet’s membrane.

In both diabetic and nondiabetic corneas, CML immunoreactivity was found in endothelial cells. Human corneal endothelial cells do not proliferate in vivo, and the number of endothelial cells gradually decreases with aging.41 Because the correlation between the accumulation of AGEs and the aging process has been shown in other tissues,17 23 42 43 the accumulation of AGEs might cause the decrease of corneal endothelial cells with aging. Further studies are necessary to elucidate these points.

In summary, the present study indicates that CML immunoreactivity is increased in the epithelial basement membrane of diabetic corneas and that nonenzymatic glycation of laminin reduces adhesion and spreading of corneal epithelial cells. Thus, the accumulation of AGEs on the basement membrane, particularly on laminin, may play a causative role in diabetic corneal epitheliopathy. With the relative accessibility of the cornea to the local drug delivery, the potential for the development of anti-AGE drugs for diabetic corneal disorders appears promising.


   Acknowledgements
 
The authors thank Kaoru Sasaki (Tane Memorial Eye Hospital, Osaka, Japan), Masatsugu Nakamura (Santen Pharmaceutical, Nara, Japan), and Hitoshi Watanabe (Osaka University, Department of Ophthalmology, Osaka, Japan) for providing SV-40–immortalized human corneal epithelial cells.


   Footnotes
 
Submitted for publication January 7, 1999; revised August 10 and September 13, 1999; accepted September 23, 1999.

Commercial relationships policy: N.

Corresponding author: Shiro Amano, Department of Ophthalmology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. amanos-tky{at}umin.ac.jp


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Schultz, RO, Van Horn, DL, Peters, MA, Klewin, KM, Schutten, WH (1981) Diabetic keratopathy Trans Am Ophthalmol Soc 79,180-189[Medline][Order article via Infotrieve]
  2. Taylor, HR, Kimsey, RA (1981) Corneal epithelial basement membrane changes in diabetes Invest Ophthalmol Vis Sci 20,548-553[Abstract/Free Full Text]
  3. Azar, DT, Spurr–Michaud, SJ, Tisdale, AS, Gipson, IK (1989) Decreased penetration of anchoring fibrils into the diabetic stroma Arch Ophthalmol 107,1520-1523[Abstract]
  4. Friend, J, Ishii, Y, Thoft, RA (1982) Corneal epithelial changes in diabetic rats Ophthalmic Res 14,269-278[Medline][Order article via Infotrieve]
  5. Shultz, RO, Matsuda, M, Yee, RW, Edelhauser, HF, Schultz, KJ (1984) Corneal endothelial changes in type I and type II diabetes mellitus Am J Ophthalmol 98,401-410[Medline][Order article via Infotrieve]
  6. Tsubota, K, Chiba, K, Shimazaki, J. (1991) Corneal epithelium in diabetic patients Cornea 10,156-160[Medline][Order article via Infotrieve]
  7. Hosotani, H, Ohashi, Y, Yamada, M, Tsubota, K. (1995) Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112 Am J Ophthalmol 119,288-294[Medline][Order article via Infotrieve]
  8. Perry, HD, Foulks, GN, Thoft, RA, Tolentino, FI (1978) Corneal complications after closed vitrectomy through the pars plana Arch Ophthalmol 96,1401-1403[Abstract]
  9. Brightbill, FS, Myers, FL, Bresnick, GH (1978) Postvitrectomy keratopathy Am J Ophthalmol 85,651-655[Medline][Order article via Infotrieve]
  10. Foulks, GN, Thoft, RA, Perry, HD, Tolentino, FI (1979) Factors related to corneal epithelial complications after closed vitrectomy in diabetics Arch Ophthalmol 97,1076-1078[Abstract]
  11. Chung, H, Tolentino, FI, Cajita, VN, Acosta, J, Refojo, MF (1988) Reevaluation of corneal complications after closed vitrectomy Arch Ophthalmol 106,916-919[Abstract]
  12. Ohashi, Y, Matsuda, M, Hosotani, H, et al (1988) Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy Am J Ophthalmol 105,233-238[Medline][Order article via Infotrieve]
  13. Ohguro, N, Matsuda, M, Ohashi, Y, Fukuda, M. (1995) Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients Br J Ophthalmol 79,1074-1077[Abstract/Free Full Text]
  14. Makita, Z, Radoff, S, Rayfield, EJ, et al (1991) Advanced glycosylation end products in patients with diabetic nephropathy N Engl J Med 325,836-842[Abstract]
  15. Murata, T, Nagai, R, Ishibashi, T, Inomata, H, Ikeda, K, Horiuchi, S. (1997) The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas Diabetologia 40,764-769[Medline][Order article via Infotrieve]
  16. Dunn, JA, Patrick, JS, Thorpe, SR, Baynes, JW (1989) Oxidation of glycated proteins: age-dependent accumulation of N{epsilon}-(carboxymethyl) lysine in lens proteins Biochemistry 28,9464-9468[Medline][Order article via Infotrieve]
  17. Araki, N, Ueno, N, Chakrabarti, B, Morino, Y, Horiuchi, S. (1992) Immunochemical evidence for the presence of advanced glycation end products and its positive correlation with aging J Biol Chem 267,10211-10214[Abstract/Free Full Text]
  18. Reddy, S, Bichler, J, Wells–Knecht, KJ, Thorpe, SR, Baynes, JW (1995) N{epsilon}-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins Biochemistry 34,10872-10878[Medline][Order article via Infotrieve]
  19. Ikeda, K, Higashi, T, Sano, H, et al (1996) N{epsilon}-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction Biochemistry 35,8075-8083[Medline][Order article via Infotrieve]
  20. Davies, PD, Duncan, G, Pynsent, PB, Arber, DL, Lucas, VA (1984) Aqueous humour glucose concentration in cataract patients and its effect on the lens Exp Eye Res 39,605-609[Medline][Order article via Infotrieve]
  21. Horiuchi, S, Araki, N, Morino, Y. (1991) Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: evidence for the presence of a common structure J Biol Chem 266,7329-7332[Abstract/Free Full Text]
  22. Shi, SR, Key, ME, Kalra, KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections J Histochem Cytochem 39,741-748[Abstract]
  23. Cuevas, EC, Bateman, AC, Wilkins, BS, et al (1994) Microwave antigen retrieval in immunocytochemistry: a study of 80 antibodies J Clin Pathol 47,448-452[Abstract/Free Full Text]
  24. Araki–Sasaki, K, Ohashi, Y, Sasabe, T, et al (1995) An SV40-immortalized human corneal epithelial cell line and its characterization Invest Ophthalmol Vis Sci 36,614-621[Abstract/Free Full Text]
  25. Kimura, T, Takamatsu, J, Ikeda, K, Kondo, A, Miyakawa, T, Horiuchi, S. (1996) Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons Neurosci Lett 208,53-56[Medline][Order article via Infotrieve]
  26. Millin, JA, Golub, BM, Foster, CS (1986) Human basement membrane components of keratoconus and normal corneas Invest Ophthalmol Vis Sci 27,604-607[Abstract/Free Full Text]
  27. Marshall, GE, Konstas, AG, Lee, WR (1991) Immunogold fine structural localization of extracellular matrix components in aged human cornea, I: types I-IV collagen and laminin Graefes Arch Clin Exp Ophthalmol 229,157-163[Medline][Order article via Infotrieve]
  28. Ljubimov, AV, Burgeson, RE, Butkowski, RJ, Michael, AF, Sun, TT, Kenny, MC (1995) Human corneal basement membrane heterogeneity: topographical differences in the expression of type IV collagen and laminin isoforms Lab Invest 72,461-473[Medline][Order article via Infotrieve]
  29. Abrahamson, DR, Caulfield, JP (1982) Proteinuria and structural alterations in rat glomerular basement membranes induced by intravenously injected anti-laminin immunoglobulin G J Exp Med 156,128-145[Abstract/Free Full Text]
  30. Trier, JS, Allan, CH, Abrahamson, DR, Hagen, SJ (1990) Epithelial basement membrane of mouse jejunum: evidence for laminin turnover along the entire crypt-villus axis J Clin Invest 86,87-95
  31. Snip, RC, Thoft, RA, Tolentino, FI (1980) Similar epithelial healing rates of the corneas of diabetic and nondiabetic patients Am J Ophthalmol 90,463-468[Medline][Order article via Infotrieve]
  32. Macaluso, DC, Feldman, ST (1997) Pathogenesis of sterile corneal erosions and ulcerations Krachmer, JH Mannis, MJ Holland, EJ eds. Cornea ,199-212 Mosby–Year Book St. Louis.
  33. Anderson, SS, Kim, Y, Tsilibary, EC (1994) Effects of matrix glycation on mesangial cell adhesion, spreading and proliferation Kidney Int 46,1359-1367[Medline][Order article via Infotrieve]
  34. Krishnamurti, U, Rondeau, E, Sraer, J, Michael, AF, Tsilibary, EC (1997) Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix J Biol Chem 272,27966-27970[Abstract/Free Full Text]
  35. Krantz, S, Lober, M, Thiele, M, Teuscher, E. (1988) Diminished adhesion of endothelial aortic cells on fibronectin and collagen layers after nonenzymatic glycation Exp Clin Endocrinol 91,155-160[Medline][Order article via Infotrieve]
  36. Bobbink, IWG, Boer, HCd, Tekelenburg, WLH, Banga, J, Groot, PGd (1997) Effect of extracellular matrix glycation on endothelial cell adhesion and spreading: involvement of vitronectin Diabetes 46,87-93[Abstract]
  37. Ljubimov, AV, Huang, Z, Huang, GH, et al (1998) Human corneal epithelial basement membrane and integrin alterations in diabetes and diabetic retinopathy J Histochem Cytochem 46,1033-1041[Abstract/Free Full Text]
  38. Nagai, R, Ikeda, K, Higashi, T, et al (1997) Hydroxyl radical mediates N{epsilon}-(carboxymethyl) lysine formation from Amadori product Biochem Biophys Res Commun 234,167-172[Medline][Order article via Infotrieve]
  39. Baynes, JW (1991) Role of oxidative stress in development of complications in diabetes Diabetes 40,405-412[Abstract]
  40. Fu, MX, Wells–Knecht, KJ, Blackledge, JA, Lyons, TJ, Thorpe, SR, Baynes, JW (1994) Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction Diabetes 43,676-683[Abstract]
  41. Arffa, RC (1997) Anatomy Arffa, RC eds. Grayson’s Diseases of the Cornea ,1-22 Mosby–Year Book St. Louis.
  42. Dunn, JA, Patrick, JS, Thorpe, SR, Baynes, JW (1989) Oxidation of glycated proteins: age-dependent accumulation of N{epsilon}-(carboxymethyl) lysine in lens proteins Biochemistry 28,9464-9468
  43. Dunn, JA, McCance, DR, Thorpe, SR, Lyons, TJ, Baynes, JW (1991) Age-dependent accumulation of N{epsilon}-(carboxymethyl) lysine and N{epsilon}-(carboxymethyl) hydroxylysine in human skin collagen Biochemistry 30,1205-1210[Medline][Order article via Infotrieve]



This article has been cited by other articles:


Home page
 IOVSHome page
M. Wakuta, N. Morishige, T.-i. Chikama, K. Seki, T. Nagano, and T. Nishida
Delayed Wound Closure and Phenotypic Changes in Corneal Epithelium of the Spontaneously Diabetic Goto-Kakizaki Rat
Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 590 - 596.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Kaji, T. Usui, S. Ishida, K. Yamashiro, T. C. B. Moore, J. Moore, Y. Yamamoto, H. Yamamoto, and A. P. Adamis
Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products
Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 858 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
Y Kaji, R Nagai, S Amano, Y Takazawa, M Fukayama, and T Oshika
Advanced glycation end product deposits in climatic droplet keratopathy
Br. J. Ophthalmol., January 1, 2007; 91(1): 85 - 88.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Saghizadeh, A. A. Kramerov, J. Tajbakhsh, A. M. Aoki, C. Wang, N.-N. Chai, J. Y. Ljubimova, T. Sasaki, G. Sosne, M. R. J. Carlson, et al.
Proteinase and Growth Factor Alterations Revealed by Gene Microarray Analysis of Human Diabetic Corneas
Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3604 - 3615.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
Y Kaji
Prevention of diabetic keratopathy
Br. J. Ophthalmol., March 1, 2005; 89(3): 254 - 255.
[Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
M Nakahara, K Miyata, S Otani, T Miyai, R Nejima, S Yamagami, and S Amano
A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients
Br. J. Ophthalmol., March 1, 2005; 89(3): 266 - 268.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Akimoto, H. Kawakami, K. Yamamoto, E. Munetomo, T. Hida, and H. Hirano
Elevated Expression of O-GlcNAc-Modified Proteins and O-GlcNAc Transferase in Corneas of Diabetic Goto-Kakizaki Rats
Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 3802 - 3809.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Kaji, S. Amano, T. Usui, T. Oshika, K. Yamashiro, S. Ishida, K. Suzuki, S. Tanaka, A. P. Adamis, R. Nagai, et al.
Expression and Function of Receptors for Advanced Glycation End Products in Bovine Corneal Endothelial Cells
Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 521 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
A. W STITT
Advanced glycation: an important pathological event in diabetic and age related ocular disease
Br. J. Ophthalmol., June 1, 2001; 85(6): 746 - 753.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Sato, F. Mori, S. Igarashi, T. Abiko, M. Takeda, S. Ishiko, and A. Yoshida
Corneal Advanced Glycation End Products Increase in Patients With Proliferative Diabetic Retinopathy
Diabetes Care, March 1, 2001; 24(3): 479 - 482.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
M. Saghizadeh, D. J. Brown, R. Castellon, M. Chwa, G. H. Huang, J. Y. Ljubimova, S. Rosenberg, K. S. Spirin, R. B. Stolitenko, W. Adachi, et al.
Overexpression of Matrix Metalloproteinase-10 and Matrix Metalloproteinase-3 in Human Diabetic Corneas : A Possible Mechanism of Basement Membrane and Integrin Alterations
Am. J. Pathol., February 1, 2001; 158(2): 723 - 734.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
S. Amano, Y. Kaji, T. Oshika, T. Oka, R. Machinami, R. Nagai, and S. Horiuchi
Advanced glycation end products in human optic nerve head
Br. J. Ophthalmol., January 1, 2001; 85(1): 52 - 55.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaji, Y.
Right arrow Articles by Amano, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaji, Y.
Right arrow Articles by Amano, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS